Cationic liposomes

Patent metadata

Field	Value
Publication number	US-2020163880-A1
Application number	US-201816630200-A
Country	US
Kind code	A1
Filing date	Jul 13, 2018
Priority date	Jul 13, 2017
Publication date	May 28, 2020
Grant date	—

Abstract

Disclosed herein are cationic liposomes suitable for specific delivery of immunomodulating agents to monocytes and dendritic cells. The cationic liposomes comprise phospholipids, cholesterol, cationic lipids, PEG and at least one active ingredient and have a zeta potential in the range of 13-25 mV. Further disclosed are uses of such cationic liposomes in various pharmaceutical applications.

First claim

1 . A cationic liposome comprising:
a) between 0-40 mol % cholesterol, b) between 1-10 mol % PEG conjugated to a phospholipid, c) at least one cationic lipid, and d) at least one immunostimulating compound,
wherein the remaining components are phospholipids and wherein the zeta potential is in the range of 13-25 mV.

2 . The cationic liposome according to claim 1 , wherein the at least one immunostimulating compound is a ligand for an intracellular protein and/or receptor selected from the group consisting of TLR7, STING, TLR3, TLR8, TLR9, NOD1, NOD2, NOD5, NALP1, NALP2, NALP3, NALP12, NALP14, IPAF, NAIP, CIITA, RIG-I, MDA5, and LGP2.

3 . The cationic liposome according to any of the preceding claims, wherein the cationic liposome preferentially adheres to monocytes and dendritic cells in fresh whole blood when compared to adherence to granulocytes, T-lymphocytes, B-lymphocytes and/or NK cells.

4 . The cationic liposome according to any of the preceding claims, wherein the at least one immunostimulating agent is a TLR7 agonist, such as a TLR7 agonist selected from the group consisting of Formula (I), Formula (II), Formula (III) and Formula (IV).

wherein X 1 is -0-, —S—, or —NR C ;
R 1 is hydrogen, (C 1 -C 10 )alkyl, substituted (C 1 -C 10 )alkyl, C 6-10 aryl, or substituted C 6-10 aryl, C 5-9 heterocyclic, substituted C 5-9 heterocyclic;
R C is hydrogen, C 1-10 alkyl, or substituted C 1-10 alkyl; or R C and R 1 taken together with the nitrogen to which they are attached form a heterocyclic ring or a substituted heterocyclic ring;
each R 2 is independently —OH, (C 1 -C 6 )alkyl, substituted (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, substituted (C 1 -C 6 )alkoxy, —C(O)—(C 1 -C 6 )alkyl (alkanoyl), substituted —C(O)—(C 1 -C 6 )alkyl, —C(O)—(C 6 -C 10 )aryl (aroyl), substituted —C(O)—(C 6 -C 10 )aryl, —C(O)OH (carboxyl), —C(O)O(C 1 -C 6 )alkyl (alkoxycarbonyl), substituted —C(O)O(C 1 -C 6 )alkyl, —NR a R b , —C(O)NR a R b (carbamoyl), halo, nitro, or cyano, or R 2 is absent;
each R a and R b is independently hydrogen, (C 1 -C 6 )alkyl, substituted (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, substituted (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, substituted (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkanoyl, substituted (C 1 -C 6 )alkanoyl, aryl, aryl(C 1 -C 6 )alkyl, Het, Het (C 1 -C 6 )alkyl, or (C 1 -C 6 )alkoxycarbonyl;
wherein the substituents on any alkyl, aryl or heterocyclic groups are hydroxy, C 1-6 alkyl, hydroxyC 1-6 alkylene, C 1-6 alkoxy, C 3-6 cycloalkyl, C 1-6 alkoxy C 1-6 alkylene, amino, cyano, halo, or aryl;
n is 0, 1, 2, 3 or 4;
X 2 is a bond or a linking group; and
R 3 is a phospholipid comprising one or two carboxylic esters;
X 3 is —N— or —CH—;
R 4 is —CH 2 — or —CH(R 2 )—; and
k is 0 or 1;
X 4 is —O—, —S—, —NH—, —N(R d )—, —CH 2 —, or —CH(R 2 )—;
each R d is independently —OH, (C 1 -C 6 )alkyl, substituted (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, substituted (C 1 -C 6 )alkoxy, —C(0)-(C 1 -C 6 )alkyl (alkanoyl), substituted —C(0)-(C 1 -C 6 )alkyl, —C(0)-(C 6 -C 10 )aryl (aroyl), substituted —C(O)—(C 6 -C 0 )aryl, —C(0)0(C 1 -C 6 )alkyl (alkoxycarbonyl), substituted —C(0)0(C 1 -C 6 )alkyl, —C(0)NR a R b (carbamoyl);
or a tautomer thereof;
or a pharmaceutically acceptable salt or solvate thereof, and
wherein the ring system of formula (II) is a piperidine ring with one heteroatom being an N atom and with the N-atom of the piperidine ring adjacent to X 2 , and wherein the purine group in any of Formula (I), (II), (III), or (IV) is subject to tautomeric rearrangements.

5 . The cationic liposome according to claim 4 , wherein the TLR7 agonist has a structure according to Formula (IA).

6 . The cationic liposome according to any of the preceding claims wherein the content of cationic lipid in mol % multiplied by the charge of the cationic lipid is in the range of 16-30, such as 20-30, such as 20-25.

7 . The cationic liposome according to any of the preceding claims, wherein the cationic lipid is selected from the group consisting of stearylamine (SA), lauryltrimethylammonium bromide; cetyltrimethyl-ammonium bromide, myristyl trimethylammonium bromide, dimethyldioctadecylammonium bromide (DDAB), 36-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC-Cholesterol), 1,2-ditetradecanoyl-3-trimethylammonium-propane (DMTAP), 1,2-dioctadecanoyl-3-trimethylammonium-propane (DOTAP) and DOTAP derivatives such as 1,2-di-(9Z-octadecenoyl)-3-trimethylammonium-propane and 1,2-dihexadecanoyl-3-trimethylammonium-propane, 1,2-di-(9Z-octadecenoyl)-3-dimethylammonium-propane (DODAP) and DODAP derivatives such as 1,2-ditetradecanoyl-3-dimethylammonium-propane, 1,2-dihexadecanoyl-3-dimethylammonium-propane, and 1,2-dioctadecanoyl-3-dimethylammonium-propane, 1,2-di-0-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dioleoyl-c-(4′-trimethylammonium)-butanoyl-sn-glycerol (DOTB), dioctadecylamide-glycylspermine, SAINT-2, polycationic lipid 2,3-dioleyloxy-N-[2(spermine-carboxamido)ethyl]-N,N-dimethyl-1-propanaminiumtrifluoroacetate (DOSPA), 1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (EPC) and GL67™, preferably the cationic lipid is DOTAP.

8 . The cationic liposome according to any of the preceding claims, wherein the cationic lipid is 1,2-dioctadecanoyl-3-trimethylammonium-propane (DOTAP), preferably wherein the content of cationic lipid is in the range of 16-30 mol %, such as 20-30 mol %, such as 20-25 mol %.

9 . The cationic liposome according to any of the preceding claims, wherein the content of the immunostimulating compound is in the range of about 0.1-50 mol %, for example about 2-40 mol %, for example about 5-30 mol %, for example about 10-20 mol %, for example about 2.5-7.5 mol %, such as about 3-7 mol %, preferably the content of the active ingredient is about 5 mol %.

10 . A cationic liposome comprising:
a) between about 30-40 mol % POPC, such as about 35 mol % POPC, b) between about 25-35 mol % cholesterol, such as about 30 mol % cholesterol, c) between about 3-7 mol % DOPE-PEG2000, such as about 5 mol % DOPE-PEG2000, d) between about 20-30 mol % DOTAP, such as about 25 mol % DOTAP, and e) between about 2.5-7.5 mol % of the TLR7 agonist 1v270, such as about 5 mol % 1v270,
wherein the zeta potential is in the range of 13-25 mV.

11 . The cationic liposome according to any of the preceding claims, wherein the cationic liposome comprises at least one immunostimulating compound and at least one further active ingredient.

12 . The cationic liposome according to any of the preceding claims, wherein the cationic liposome comprises at least one immunostimulating compound and at least one antigen.

13 . A pharmaceutical composition comprising the cationic liposome according to any one of claims 1 - 12 .

14 . The cationic liposome according to any one of claim 1 - 12 or the pharmaceutical composition according to claim 13 , for use in prophylaxis, treatment or amelioration of cancer, an infectious disease, an inflammatory condition or disease, an autoimmune disease or allergy.

15 . A lipid-based delivery system for targeting monocytes and dendritic cells in fresh whole blood, said system providing delivery to and release of at least one immunostimulating compound to the targeted monocyte, and said system comprising:
a) between 0-40 mol % c

Assignees

• Univ Danmarks Tekniske

Inventors

• Andresen Thomas Lars
• Jensen Simon Skjøde
• Henriksen Jonas Rosager
• Parhamifar Ladan
• Lassen Rasmus Mikkel Münter

Classifications

• A61K9/1272 Primary

  comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543}) · CPC title

• A61K31/52

  Purines, e.g. adenine · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K9/1271 Primary

  Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) · CPC title